EXANE DERIVATIVES - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 159 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2022$83,000
-15.3%
60.0%0.00%
Q1 2022$98,0000.0%60.0%0.00%
Q4 2021$98,000
+10.1%
60.0%0.00%
Q3 2021$89,000
-15.2%
60.0%0.00%
Q2 2021$105,000
-23.9%
60.0%0.00%
Q1 2021$138,000
-6.8%
60.0%0.00%
Q4 2020$148,000
-40.6%
60.0%0.00%
Q3 2020$249,000
-13.2%
60.0%0.00%
Q2 2020$287,000
-24.1%
60.0%0.00%
Q1 2020$378,000
-44.2%
60.0%0.00%
Q4 2019$677,000
-99.7%
6
-99.8%
0.00%
-100.0%
Q3 2019$251,267,000
-16.6%
3,7870.0%0.04%
-15.1%
Q2 2019$301,247,000
+44795.2%
3,787
+63016.7%
0.05%
Q1 2019$671,000
+10.9%
60.0%0.00%
Q4 2018$605,000
-31.6%
6
-14.3%
0.00%
Q3 2018$884,000
+50.3%
70.0%0.00%
Q2 2018$588,000
+42.0%
70.0%0.00%
Q1 2018$414,000
-99.3%
7
-99.3%
0.00%
-100.0%
Q4 2017$55,483,000
-81.2%
950
-81.3%
0.01%
-81.8%
Q3 2017$294,608,000
+22034.3%
5,077
+46054.5%
0.06%
Q2 2017$1,331,000110.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2017
NameSharesValueWeighting ↓
WHITE SQUARE CAPITAL LLP 65,500$7,117,00011.05%
Ghost Tree Capital, LLC 70,000$7,606,0001.83%
Carmignac Gestion 2,022,792$219,776,0001.71%
Orbimed Advisors 1,120,000$121,688,0001.55%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 29,555$3,211,0001.45%
Parametrica Management Ltd 10,814$1,175,0001.16%
BB BIOTECH AG 255,719$27,784,0001.03%
SECTORAL ASSET MANAGEMENT INC 74,150$8,056,0000.89%
ALTRINSIC GLOBAL ADVISORS LLC 188,904$20,524,0000.76%
FALCON POINT CAPITAL, LLC 45,005$4,890,0000.66%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders